Pradusinstobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase I drugs for Advanced Malignancy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pradusinstobart LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pradusinstobart overview

Pradusinstobart is under development for the treatment of solid tumors including gastric cancer, metastatic uveal melanoma, head and neck carcinoma, metastatic hepatocellular carcinoma (HCC), metastatic ovarian cancer, soft tissue sarcoma and esophageal cancer. It targets programmed cell death-1 (PD-1). The drug candidate is developed based on the antibody technology platform. It is administered through intravenous and oral route.

Lyvgen Biopharma overview

Lyvgen Biopharma, is a cancer immunotherapy service provider. The company is headquartered in China.

For a complete picture of Pradusinstobart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.